Mycophenolate mofetil for lupus nephritis: an update

References

• Fernández M, Alarcón GS, Calvo-Alén J, et al. LUMINA Study Group. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 2007;57:576-84
   PubMed Web of Science ®Google Scholar
• Sánchez E, Rasmussen A, Riba L, et al. Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian-European populations. Arthritis Rheum 2012;64:3687-94
   PubMed Web of Science ®Google Scholar
• Hiraki LT, Benseler SM, Tyrrell PN, et al. Ethnic differences in pediatric systemic lupus erythematosus. J Rheumatol 2009;36:2539-46
   PubMed Web of Science ®Google Scholar
• Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005;52:2774-82
   PubMed Web of Science ®Google Scholar
• Mok CC. Understanding lupus nephritis: diagnosis, management, and treatment options. Int J Womens Health 2012;4:213-22
   PubMedGoogle Scholar
• Mok CC, Ying KY, Ng WL, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006;119:355.e25-33
   PubMed Web of Science ®Google Scholar
• Korbet SM, Schwartz MM, Evans J, Lewis EJ. Collaborative Study Group. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007;18:244-54
   PubMed Web of Science ®Google Scholar
• Hui M, Garner R, Rees F, et al. Lupus nephritis: a 15-year multi-centre experience in the UK. Lupus 2013;22:328-32
   PubMed Web of Science ®Google Scholar
• Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum 2013;65:2154-60
   PubMed Web of Science ®Google Scholar
• Appenzeller S, Clarke AE, Panopalis P, et al. The relationship between renal activity and quality of life in systemic lupus erythematosus. J Rheumatol 2009;36:947-52
   PubMed Web of Science ®Google Scholar
• Mok CC, Cheung MY, Ho LY, et al. Risk and predictors of work disability in Chinese patients with systemic lupus erythematosus. Lupus 2008;17:1103-7
   PubMed Web of Science ®Google Scholar
• Mok CC, Lai KN. Mycophenolate mofetil in lupus glomerulonephritis. Am J Kidney Dis 2002;40:447-57
   PubMed Web of Science ®Google Scholar
• Gibson WT, Hayden MR. Mycophenolate mofetil and atherosclerosis: results of animal and human studies. Ann N Y Acad Sci 2007;1110:209-21
   PubMed Web of Science ®Google Scholar
• Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-62
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28
   PubMed Web of Science ®Google Scholar
• Appel GB, Contreras G, Dooley MA, et al. Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12
   PubMed Web of Science ®Google Scholar
• Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010;77:152-60
   PubMed Web of Science ®Google Scholar
• Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-95
   PubMed Web of Science ®Google Scholar
• Bao H, Liu ZH, Xie HL, et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 2008;19:2001-10
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 2015;162:18-26
   PubMed Web of Science ®Google Scholar
• Fernández-Nebro A, de la Fuente JL, Carreño L, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus 2012;21:1063-76
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus 2009;18:767-76
   PubMed Web of Science ®Google Scholar
• Weidenbusch M, Römmele C, Schröttle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 2013;28:106-11
   PubMed Web of Science ®Google Scholar
• Díaz-Lagares C, Croca S, Sangle S, et al. UK-BIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 2012;11:357-64
   PubMed Web of Science ®Google Scholar
• Terrier B, Amoura Z, Ravaud P, et al. Club rhumatismes et inflammation. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry. Arthritis Rheum 2010;62:2458-66
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, et al. LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-26
   PubMed Web of Science ®Google Scholar
• Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280-6
   PubMed Web of Science ®Google Scholar
• Lee WA, Gu L, Miksztal AR, et al. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990;7:161-6
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118
   PubMed Web of Science ®Google Scholar
• Kaltenborn A, Schrem H. Mycophenolate mofetil in liver transplantation: a review. Ann Transplant 2013;18:685-96
   PubMed Web of Science ®Google Scholar
• Eugui EM, Mirkovich A, Allison AC. Lymphocyte selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991;33:175-83
   PubMed Web of Science ®Google Scholar
• Eugui EM, Almquist SJ, Muller CD, Allison AC. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991;33:161-73
   PubMed Web of Science ®Google Scholar
• Thomson AW, Woo J, Yao GZ, et al. Effects of combined administration of FK506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures. Transpl Immunol 1993;1:146-50
   PubMedGoogle Scholar
• Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005;80(2 Suppl):S181-90
   PubMed Web of Science ®Google Scholar
• Chang CC, Aversa G, Punnonen J, et al. Brequinar sodium, mycophenolic acid, and cyclosporin A inhibit different stages of IL-4- or IL-13-induced human IgG4 and IgE production in vitro. Ann NYAcad Sci 1993;696:108-12
   PubMed Web of Science ®Google Scholar
• Izeradjene K, Quemeneur L, Michallet MC, et al. Mycophenolate mofetil interferes with interferon gamma production in T-cell activation models. Transplant Proc 2001;33:2110-11
   PubMed Web of Science ®Google Scholar
• Nagy SE, Andersson JP, Andersson UG. Effect of mycophenolate mofetil (RS-61443) on cytokine production: Inhibition of superantigen-induced cytokines. Immunopharmacol 1993;26:11-20
   PubMed Web of Science ®Google Scholar
• Cohn RG, Mirkovich A, Dunlap B, et al. Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 1999;68:411-18
   PubMed Web of Science ®Google Scholar
• Izeradjene K, Revillard JP. Apoptosis of superantigen-activated T cells induced by mycophenolate mofetil treatment. Transplantation 2001;71:118-25
   PubMed Web of Science ®Google Scholar
• Abadja F, Videcoq C, Alamartine E, et al. Differential effect of cyclosporine and mycophenolic acid on the human regulatory T cells and TH-17 cells balance. Transplant Proc 2009;41:3367-70
   PubMed Web of Science ®Google Scholar
• Demirkiran A, Sewgobind VD, van der Weijde J, et al. Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells. Transplantation 2009;87:1062-8
   PubMed Web of Science ®Google Scholar
• Blaheta RA, Leckel K, Wittig B, et al. Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc 1999;31:1250-2
   PubMed Web of Science ®Google Scholar
• Laurent AF, Dumont S, Poindron P, Muller CD. Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substrates. Exp Hematol 1996;24:59-67
   PubMed Web of Science ®Google Scholar
• Glomsda BA, Blaheta RA, Hailer NP. Inhibition of monocyte/endothelial cell interactions and monocyte adhesion molecule expression by the immunosuppressant mycophenolate mofetil. Spinal Cord 2003;41:610-19
   PubMed Web of Science ®Google Scholar
• Senda M, DeLustro B, Eugui E, Natsumeda Y. Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation 1995;60:1143-8
   PubMed Web of Science ®Google Scholar
• Faugaret D, Lemoine R, Baron C, et al. Mycophenolic acid differentially affects dendritic cell maturation induced by tumor necrosis factor-alpha and lipopolysaccharide through a different modulation of MAPK signaling. Mol Immunol 2010;47:1848-59
   PubMed Web of Science ®Google Scholar
• Hauser IA, Renders L, Radeke HH, et al. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 1999;14:58-63
   PubMed Web of Science ®Google Scholar
• Ziswiler R, Steinmann-Niggli K, Kappeler A, et al. A new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J Am Soc Nephrol 1998;9:2055-66
   PubMed Web of Science ®Google Scholar
• Shui H, Gao P, Si X, Ding G. Mycophenolic acid inhibits albumin-induced MCP-1 expression in renal tubular epithelial cells through the p38 MAPK pathway. Mol Biol Rep 2010;37:1749-54
   PubMed Web of Science ®Google Scholar
• Park J, Chang HK, Ha H, et al. Mycophenolic acid inhibits cell proliferation and extracellular matrix synthesis in rat vascular smooth muscle cells through direct and indirect inhibition of cellular reactive oxygen species. J Surg Res 2008;150:17-23
   PubMed Web of Science ®Google Scholar
• Shimizu H, Takahashi M, Takeda S, et al. Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation 2004;77:1661-7
   PubMed Web of Science ®Google Scholar
• Ahn HJ, Park J, Song JS, et al. Mycophenolic acid inhibits oleic acid-induced vascular smooth muscle cell activation by inhibiting cellular reactive oxygen species. Transplantation 2007;84:634-8
   PubMed Web of Science ®Google Scholar
• Morath C, Reuter H, Simon V, et al. Effects of mycophenolic acid on human fibroblast proliferation, migration and adhesion in vitro and in vivo. Am J Transplant 2008;8:1786-97
   PubMed Web of Science ®Google Scholar
• Biermann MH, Veissi S, Maueröder C, et al. The role of dead cell clearance in the etiology and pathogenesis of systemic lupus erythematosus: dendritic cells as potential targets. Expert Rev Clin Immunol 2014;10:1151-64
   PubMed Web of Science ®Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, et al. American college of rheumatology. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012;64:797-808
   PubMed Web of Science ®Google Scholar
• Bertsias GK, Tektonidou M, Amoura Z, et al. European league against rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771-82
   PubMed Web of Science ®Google Scholar
• Mok CC, Yap DY, Navarra SV, et al. Asian Lupus Nephritis Network (ALNN). Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology (Carlton) 2014;19:11-20
   PubMed Web of Science ®Google Scholar
• Rovin BH, Parikh SV, Hebert LA, et al. Lupus nephritis: induction therapy in severe lupus nephritis-should MMF be considered the drug of choice? Clin J Am Soc Nephrol 2013;8:147-53
   PubMed Web of Science ®Google Scholar
• Kamanamool N, McEvoy M, Attia J, et al. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine (Baltimore) 2010;89:227-35
   PubMed Web of Science ®Google Scholar
• Henderson LK, Masson P, Craig JC, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2013;61:74-87
   PubMed Web of Science ®Google Scholar
• Mok CC, Tong KH, To CH, et al. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 2005;68:813-17
   PubMed Web of Science ®Google Scholar
• Szeto CC, Kwan BC, Lai FM, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford) 2008;47:1678-81
   PubMed Web of Science ®Google Scholar
• Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with Tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis 2011;57:235-44
   PubMed Web of Science ®Google Scholar
• Li X, Ren H, Zhang Q, et al. Mycophenolate mofetil or Tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant 2012;27:1467-72
   PubMed Web of Science ®Google Scholar
• Ekberg H, Tedesco-Silva H, Demirbas A, et al. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-75
   PubMed Web of Science ®Google Scholar
• Krämer BK, Del Castillo D, Margreiter R, et al. European Tacrolimus versus Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results. Nephrol Dial Transplant 2008;23:2386-92
   PubMed Web of Science ®Google Scholar
• Silva HTJr, Yang HC, Meier-Kriesche HU, et al. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. Transplantation 2014;97:636-41
   PubMed Web of Science ®Google Scholar
• Penninga L, Møller CH, Gustafsson F, et al. Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur J Clin Pharmacol 2010;66:1177-87
   PubMed Web of Science ®Google Scholar
• Mok CC, Ying KY, Yim CW, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Mok CC, To CH, Yu KL, Ho LY. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study. Lupus 2013;22:1135-41
   PubMed Web of Science ®Google Scholar
• Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther 2013;8:87-100
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33
   PubMed Web of Science ®Google Scholar
• Rovin BH, Parikh SV. Lupus nephritis: the evolving role of novel therapeutics. Am J Kidney Dis 2014;63:677-90
   PubMed Web of Science ®Google Scholar
• Trial of rituximab and mycophenolate mofetil without oral steroids for lupus nephritis (RITUXILUP). Available from: https://clinicaltrials.gov/ct2/show/NCT01773616
   Google Scholar
• Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 2013;65:2368-79
   PubMed Web of Science ®Google Scholar
• Stohl W. Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes). Arthritis Res Ther 2010;12:111
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012;14:R33
   PubMed Web of Science ®Google Scholar
• Mok CC. Abatacept for systemic lupus erythematosus: the outlook. Exp Opin Biol Ther 2012;12:1559-61
   PubMed Web of Science ®Google Scholar
• Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 2014;66:379-89
   PubMed Web of Science ®Google Scholar
• Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term follow-up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002;46:995-1002
   PubMed Web of Science ®Google Scholar
• Moroni G, Doria A, Mosca M, et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006;1:925-32
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Austin HA III, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5
   PubMed Web of Science ®Google Scholar
• Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80
   PubMed Web of Science ®Google Scholar
• Houssiau FA, D’Cruz D, Sangle S, et al. MAINTAIN nephritis trial group. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69:2083-9
   PubMed Web of Science ®Google Scholar
• Stoenoiu MS, Aydin S, Tektonidou M, et al. Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. Nephrol Dial Transplant 2012;27:1924-30
   PubMed Web of Science ®Google Scholar
• Tamirou F, D’Cruz D, Sangle S, et al. the MAINTAIN Nephritis Trial Group. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Yap DY, Ma MK, Mok MM, et al. Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis. Rheumatology (Oxford) 2013;52:480-6
   PubMed Web of Science ®Google Scholar
• Maneiro JR, Lopez-Canoa N, Salgado E, Gomez-Reino JJ. Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis. Rheumatology (Oxford) 2014;53:834-8
   PubMed Web of Science ®Google Scholar
• Mok CC. Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. Nat Rev Nephrol 2009;5:212-20
   PubMed Web of Science ®Google Scholar
• Cortés-Hernández J, Torres-Salido MT, Medrano AS, et al. Long-term outcomes–mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant 2010;25:3939-48
   PubMed Web of Science ®Google Scholar
• Kuypers DR, de Jonge H, Naesens M, et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 2008;30:673-83
   PubMed Web of Science ®Google Scholar
• Bolin PJr, Gohh R, Kandaswamy R, et al. Mycophenolic acid in kidney transplant patients with diabetes mellitus: does the formulation matter? Transplant Rev (Orlando) 2011;25:117-23
   PubMedGoogle Scholar
• Brum S, Nolasco F, Sousa J, et al. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil. Transplant Proc 2008;40:752-4
   PubMed Web of Science ®Google Scholar
• Pisoni CN, D’Cruz DP. The safety of mycophenolate mofetil in pregnancy. Expert Opin Drug Saf 2008;7:219-22
   PubMed Web of Science ®Google Scholar
• Andrade Vila JH, da Silva JP, Guilhen CJ, et al. Even low dose of mycophenolate mofetil in a mother recipient of heart transplant can seriously damage the fetus. Transplantation 2008;86:369-70
   PubMed Web of Science ®Google Scholar
• van Gelder T, Berden JH, Berger SP. To TDM or not to TDM in lupus nephritis patients treated with MMF? Nephrol Dial Transplant 2015;30:560-4
   PubMed Web of Science ®Google Scholar
• Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003;3:534-42
   PubMed Web of Science ®Google Scholar
• Zahr N, Arnaud L, Marquet P, et al. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum 2010;62:2047-54
   PubMed Web of Science ®Google Scholar
• Sherwin CM, Sagcal-Gironella AC, Fukuda T, et al. Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. Br J Clin Pharmacol 2012;73:727-40
   PubMed Web of Science ®Google Scholar
• Hesselink DA, van Gelder T. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther 2005;78:317-21
   PubMed Web of Science ®Google Scholar
• Staatz CE, Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol 2014;88:1351-89
   PubMed Web of Science ®Google Scholar
• Lertdumrongluk P, Somparn P, Kittanamongkolchai W. Tet al. Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney Int 2010;78:389-95
   PubMed Web of Science ®Google Scholar
• Kittanamongkolchai W, Rukrung C, Supasiri T, et al. Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis. Lupus 2013;22:727-32
   PubMed Web of Science ®Google Scholar
• Neumann I, Fuhrmann H, Fang IF, et al. Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Nephrol Dial Transplant 2008;23:3514-20
   PubMed Web of Science ®Google Scholar
• Djabarouti S, Breilh D, Duffau P, et al. Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. Arthritis Res Ther 2010;12:R217
   PubMed Web of Science ®Google Scholar
• Abd Rahman AN, Tett SE, Abdul Gafor HA, et al. Exposure-effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritis. Br J Clin Pharmacol 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Zabotti A, Baraldo M, Quartuccio L, et al. Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring. Clin Rheumatol 2015;34:171-4
   PubMed Web of Science ®Google Scholar